Astera Labs vs. Marvell Technology: Which Tech Stock Is a Better Buy in 2026?

Astera Labs generated 2025 revenue of $852.5 million, up 115% year over year, with roughly $219 million of net income and $282 million of free cash flow; analysts expect 87% annualized revenue growth over the next two years. Marvell reported nearly $8.2 billion of fiscal 2026 revenue, up about 42%, and approximately $2.7 billion in net income, while trading at lower valuation multiples than Astera (60.9x forward P/E and 23.7x sales versus 89.8x and 51.2x). The article favors Astera for its faster AI-data-center growth opportunity, but highlights material concentration risk, including one customer contributing more than 70% of Astera's 2025 revenue, alongside supply-chain and geopolitical exposure.

Analysis

The relevant distinction is not simply growth versus value: ALAB is a concentrated attach-rate bet on a small number of next-generation AI platform ramps, while MRVL is a broader bet on cloud networking and custom-silicon budgets. ALAB's valuation leaves little room for a normal product-transition air pocket; a single hyperscaler qualification delay, inventory digestion, or pricing concession could drive a disproportionate multiple reset. Conversely, successful Scorpio adoption would validate rising connectivity content per accelerator cluster and can sustain revenue upside beyond currently modeled growth.

MRVL's lower relative valuation is warranted partly by its greater exposure to networking-cycle timing and a more complex mix of custom programs, but its operating-margin target creates a clearer earnings-revision pathway over the next 12-18 months. The underappreciated risk is that hyperscalers optimize rack architecture toward fewer, more integrated components: this would pressure merchant connectivity vendors even if aggregate AI capex remains strong. NVDA's platform roadmap and hyperscaler capex commentary are more important leading indicators for both names than headline AI spending estimates.

The cleanest near-term setup is relative rather than directional. Consensus enthusiasm appears concentrated in ALAB's revenue trajectory, yet its SBC-adjusted cash economics and customer concentration make it vulnerable if sell-side estimates stop rising; MRVL has more scope for margin-driven rerating if execution remains intact. TSM is a second-order beneficiary of continued volume growth, but geopolitical-risk premia can prevent its equity from fully reflecting semiconductor demand strength.

Key Decisions for Investors

• Initiate a 3-6 month long MRVL / short ALAB pair, dollar-neutral: MRVL offers a more defensible earnings-and-margin catalyst while ALAB carries greater customer-concentration and de-rating risk. Target 15-20% relative outperformance; stop if ALAB reports material upside from a new hyperscaler or MRVL cuts its operating-margin timeline.
• For long-only AI exposure, wait for ALAB's next earnings release before adding: require evidence of customer diversification, Scorpio ramp conversion into backlog or revenue guidance, and limited gross-margin dilution. Absent those datapoints, the risk/reward at roughly 90x forward earnings is unfavorable to initiating ahead of results.
• Add MRVL on post-earnings weakness only if data-center growth and the 38-40% operating-margin path remain intact; use a 12-18 month horizon. Thesis is falsified by a material cloud-custom-program delay, sustained gross-margin erosion, or export-control-driven guidance reduction.
• Maintain TSM as the supply-chain hedge to continued AI connectivity demand, but size below pure demand beneficiaries until Taiwan geopolitical risk is compensated by valuation. A meaningful escalation in cross-strait risk would dominate otherwise positive wafer-volume fundamentals.